Publications 2026

Sommervoll FÅ, Horndalsveen H, Sommervoll DE, Koivonen J, Halvorsen TO, Grønberg BH, Aanerud M, Cicenas S, Helbekkmo N, Ahvonen J, Silvoniemi M, Barrera G, Bjaanæs MM, Haakensen V, Öjlert Å, Oselin K, Helland Å, Madebo T (2026)
How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?
Acta Oncol, 65, 232-240
DOI 10.2340/1651-226X.2026.45040, PubMed 41854264

Stensland EM, Stensgaard S, Eide IJZ, Nilssen Y, Horndalsveen H, Cicenas S, Grønberg BH, Ekman S, Hansen KH, Sorensen BS, Brustugun OT (2026)
Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study)
Lung Cancer, 214, 109338
DOI 10.1016/j.lungcan.2026.109338, PubMed 41723914

Publications 2025

Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Koivunen J, Oselin K, Cicenas S, Helbekkmo N, Aanerud M, Ahvonen J, Silvoniemi M, Bjaanæs MM, Farooqi S, Nebdal D, Dalsgaard AM, Danielsen BK, Børve M, Dalen TS, Öjlert ÅK, Helland Å (2025)
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
Front Oncol, 15, 1681420
DOI 10.3389/fonc.2025.1681420, PubMed 41199847

Publications 2024

Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD (2024)
Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
Front Immunol, 15, 1480183
DOI 10.3389/fimmu.2024.1480183, PubMed 39687621

Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, Grønberg BH, Haakensen VD, Helland Å (2024)
Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial
Front Oncol, 14, 1412716
DOI 10.3389/fonc.2024.1412716, PubMed 39148905

Publications 2023

Langberg CW, Horndalsveen H, Helland Å, Haakensen VD (2023)
Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
Front Oncol, 13, 1217424
DOI 10.3389/fonc.2023.1217424, PubMed 37476372

Publications 2022

Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD (2022)
[Checkpoint inhibitor-induced myocarditis]
Tidsskr Nor Laegeforen, 142 (18)
DOI 10.4045/tidsskr.21.0817, PubMed 36511752

Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
Mol Oncol, 17 (3), 487-498
DOI 10.1002/1878-0261.13330, PubMed 36330681

Publications 2021

Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
J Transl Med, 19 (1), 232
DOI 10.1186/s12967-021-02905-3, PubMed 34059094

Publications 2017

Vandraas KF, Torfoss D, Berstad AE, Horndalsveen H, Turowski G (2017)
[Cancer patient in his 50's with troublesome palpitations]
Tidsskr Nor Laegeforen, 137 (16)
DOI 10.4045/tidsskr.17.0204, PubMed 28871750

Vandraas KF, Torfoss D, Berstad AE, Horndalsveen H, Turowski G (2017)
Cancer patient in the 50s with troublesome palpitations
Tidsskr. Nor. Laegeforen., 137 (16), 1210-1213